Nobelpharma America Selects AllianceRx Walgreens and Total Care Rx to Distribute Hyftor
PANTHERx Rare announced that it has been selected by Aadi Bioscience (Aadi) as the exclusive U.S. pharmacy distribution partner for new drug FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound)
Investment positions Orsini Specialty Pharmacy for continued expansion of patient access and support services across therapies for highly complex and rare diseases
PANTHERx Rare was recently selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole).
The Vistria Group, LP (Vistria) recently announced the acquisition of BioCare, Inc. (BioCare), a leading specialty pharmaceutical distribution partner that provides distribution, specialty pharmacy and logistics services
Aetna recently announced an initiative to launch a designated network to cover new gene therapies for rare diseases. This follows an initiative by CVS Health in 2019 to provide self-insured employers with a stop-loss program with Aetna health plans and cover gene therapies
ChemoCentryx selected only Amber Specialty Pharmacy and PANTHERx as its limited distribution network for Tavenos
Optum® Frontier Therapies, a specialty pharmacy dedicated to people with rare disease, was founded to optimize every aspect of advanced therapeutics, from the point of prescribing to treatment and beyond